Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trialJeffrey E. Rubnitz, Dario Campana, Stanley Pounds et al.|The Lancet Oncology|2010Cited by 586
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation studySeth E. Karol, Jeffrey E. Rubnitz, Thomas Alexander et al.|The Lancet Oncology|2020Cited by 167
Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute LeukemiaThomas Alexander, Jeffrey E. Rubnitz, Norman J. Lacayo et al.|Journal of Clinical Oncology|2016Cited by 121